CCM
KYNB

Connective Capital Management’s Kyntra Bio KYNB Stock Holding History

Connective Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,000
Closed -$79.5K – 80
2025
Q2 		$79.5K Buy
+15,000
New +$109K 0.07% 46

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Connective Capital Management's KYNB Position: Q3 2025 in Review

Connective Capital Management sold out of Kyntra Bio (KYNB) in Q3 2025, closing a stake of 15,000 shares — an estimated $79.5K sold.

Connective Capital Management first reported a position in KYNB in Q2 2025 and held it in 1 quarter. The position peaked at $79.5K in Q2 2025. 32 funds tracked by Wall St. Rank hold KYNB as of Q3 2025.

  • Connective Capital Management reported no remaining Kyntra Bio position as of Q3 2025 after selling out during the quarter.
  • Connective Capital Management sold 15,000 Kyntra Bio shares in Q3 2025, an estimated $79.5K.
  • Connective Capital Management first reported a position in Kyntra Bio in Q2 2025 and held it in 1 quarter.
  • Connective Capital Management's Kyntra Bio position peaked at $79.5K in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2025.

Based on Connective Capital Management's 13F filing for Q3 2025, filed 17 Nov 2025.